within Pharmacolibrary.Drugs.ATC.L;

model L01FB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.000555,
    adminDuration  = 600,
    adminMass      = 0.0018,
    adminCount     = 1,
    Vd             = 0.0123,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody-drug conjugate used in the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It is approved for medical use and works by delivering a cytotoxic agent directly to cancerous B-cells expressing CD22.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported from clinical studies in adult patients with relapsed or refractory B-cell precursor ALL following intravenous administration.</p><h4>References</h4><ol><li><p>Advani, A, et al., &amp; Fayad, L (2010). Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin&#x27;s lymphoma: results of a phase I study. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 28(12) 2085–2093. DOI:<a href=&quot;https://doi.org/10.1200/JCO.2009.25.1900&quot;>10.1200/JCO.2009.25.1900</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20308665/&quot;>https://pubmed.ncbi.nlm.nih.gov/20308665</a></p></li><li><p>Kantarjian, H, et al., &amp; O&#x27;Brien, S (2013). Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. <i>Cancer</i> 119(15) 2728–2736. DOI:<a href=&quot;https://doi.org/10.1002/cncr.28136&quot;>10.1002/cncr.28136</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23633004/&quot;>https://pubmed.ncbi.nlm.nih.gov/23633004</a></p></li><li><p>Ogura, M, et al., &amp; Ohata, J (2010). Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. <i>Cancer science</i> 101(8) 1840–1845. DOI:<a href=&quot;https://doi.org/10.1111/j.1349-7006.2010.01601.x&quot;>10.1111/j.1349-7006.2010.01601.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20491780/&quot;>https://pubmed.ncbi.nlm.nih.gov/20491780</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FB01;
